Optimizing immunomodulatory therapy for MS patients: an integrated management model

References 

1. Goodin DS, Frohman EM, Garmany GP, et al.  Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178
   • MEDLINE
   • CrossRef
2. National Multiple Sclerosis Society . In: Disease Management Consensus Statement. New York: National Multiple Sclerosis Society; 1998;p. 1–8
3. Oger J, Freedman M. Consensus statement of the Canadian MS clinics network on: the use of disease modifying agents in multiple sclerosis. Can. J. Neurol. Sci. 1999;26:274–275
   • MEDLINE
4. Freedman MS, Blumhardt LD, Brochet B, et al.  International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult. Scler. 2002;8:19–23
   • MEDLINE
   • CrossRef
5. Paty DW, McFarland H. Magnetic resonance techniques to monitor the long term evolution of multiple sclerosis pathology and to monitor definitive clinical trials. J. Neurol. Psychiatry. 1998;64(Suppl. 1):S47–S54
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452
   • MEDLINE
   • CrossRef
7. Freedman MS, Jeffery DR, Wolinsky JS. Optimizing immunomodulatory therapy for MS patients. Int. J. MS Care. June 2002; (suppl.)